Extended anterior craniofacial resection for intracranial extension of malignant tumors

Bilsky, Mark H.; Kraus, Dennis H.; Strong, Elliót W.; Harrison, Louis B.; Gutin, Philip H.; Shah, Jatin P.

doi:10.1016/s0002-9610(97)00172-4

Cited by 45 publications

(31 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several articles on patients who underwent craniofacial resection reported results as good as ours, but the results could not be included in the metaanalysis either because of large numbers of tumors with noncarcinoma histologies or because of a short followup. 8,9,46,[197][198][199] Nevertheless, several reports related outcomes better than ours for patients with squamous cell carcinoma, 48,56,106,100,110,117,132,137,147,160,168,176 for patients with glandular carcinoma, 160,168,184 and for patients with adenocarcinoma. 136,146 The systematic review revealed a steady improvement in treatment results for patients with squamous cell carcinoma and glandular carcinoma (Fig.…”

Section: Histologymentioning

confidence: 77%

Nasal and paranasal sinus carcinoma: Are we making progress?

Dulguerov

Jacobsen

Allal

et al. 2001

Cancer

522

506

View full text Add to dashboard Cite

Section: Histologymentioning

confidence: 77%

Nasal and paranasal sinus carcinoma: Are we making progress?

Dulguerov

Jacobsen

Allal

et al. 2001

Cancer

522

506

View full text Add to dashboard Cite

“…12,13,39,40 At present, most reports in the literature advocate CFR in combination with radiation therapy, but it remains unclear whether adjuvant radiation therapy provides improved survival over complete tumor resection alone. [12][13][14][15][16][17][18][39][40][41] Most of the patients in this series were treated with CFR followed by radiation therapy. Twelve of the 20 patients examined with primary disease had no evidence of disease with a median followup of 3.9 years.…”

Section: Discussionmentioning

confidence: 99%

Esthesioneuroblastoma: The Johns Hopkins experience

et al. 2000

View full text Add to dashboard Cite

Background Esthesioneuroblastoma (ENB) is an uncommon malignant neoplasm of the upper nasal cavity. Therapeutic management approaches for this neoplasm lack uniformity and there is no universally accepted staging system. Methods A retrospective review of 27 patients with histologically confirmed ENB managed at The Johns Hopkins Hospital. Results Eighty‐five percent of patients had surgical resection as part of their disease management. Complete surgical resection was achieved in 62% of patients who had a craniofacial resection. Eighty percent of patients with negative surgical margins remain with no evidence of disease, with a median follow‐up of 5.6 years. Adjuvant radiation therapy was beneficial to 62% of patients with positive surgical margins. Clinical responses were observed with cisplatin‐ and etoposide‐containing chemotherapy regimens in patients with advanced disease. A revised staging system based on our experience is proposed. Conclusions ENB is best managed by craniofacial resection with complete tumor resection. Adjuvant radiation therapy is warranted in patients that remain with positive histologic margins of resection. Chemotherapy with cisplatin‐ and etoposide‐containing regimens may be useful for palliation of advanced disease. © 2000 John Wiley & Sons, Inc. Head Neck 22: 550–558, 2000

show abstract

“…4 Different treatment modalities have been proposed, including or combining craniofacial resection, radiotherapy, and chemotherapy. [5][6][7][8][9] However, no standard therapy exists for this tumor owing to its rarity and a lack of controlled studies. This study retrospectively reports the 35-year experience of a unique skull base surgery tertiary referral center gathering 28 patients mostly treated by surgery combined with radiotherapy.…”

mentioning

confidence: 99%